All In Biotech

Drug Trial Radar · NCT02811861

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)

Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,069 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,069

Actual

Start

Oct 13, 2016

Primary completion

Aug 28, 2020

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).

Conditions

  • Renal Cell Carcinoma

Interventions

  • LenvatinibDrug

  • EverolimusDrug

  • PembrolizumabDrug

  • SunitinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) by Independent Imaging Review (IIR)Time frame: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)

Locations

183 sites in 20 countries. Site status is shown where the registry gives one.

  • Stanford School of Medicine

    Stanford, California

  • Boca Raton Community Hospital

    Boca Raton, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • University of Miami

    Miami, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Florida Hospital Cancer Institute

    Orlando, Florida

  • Florida Cancer Specialists ( North Region)

    St. Petersburg, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Joliet Oncology - Hematology Associates

    Joliet, Illinois

  • Healthcare Research Network III, LLC

    Tinley Park, Illinois

  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC

    Overland Park, Kansas

  • Cotton-Oneil Clinical Research Center

    Topeka, Kansas

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Associates in Oncology & Hematology, PC

    Bethesda, Maryland

  • Massachusetts General Hospital- MGH

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Center

    Detroit, Michigan

  • GU Research Network

    Omaha, Nebraska

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Hackensack Medical Center

    Hackensack, New Jersey

  • Rosewell Park Cancer Institute

    Buffalo, New York

  • Broome Oncology

    Johnson City, New York

  • Weill Cornell Medical College New York Presbyterian Hospital

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Mission Hospital_ Cancer Care of Western North Carolina

    Asheville, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • SCRI - Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology, P.A.

    Dallas, Texas

  • Texas Oncology PA

    Fort Worth, Texas

  • Texas Oncology PA - McAllen

    McAllen, Texas

  • Texas Oncology PA - Paris

    Paris, Texas

  • USOR Texas Oncology

    The Woodlands, Texas

  • Texas Oncology PA - Tyler

    Tyler, Texas

  • Royal Hobart Hospital

    Hobart, Australia

  • Macquarie University Hospital

    Macquarie Park, Australia

  • ICON Cancer Foundation

    South Brisbane, Australia

  • Sunshine Hospital

    St Albans, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.